• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Cue Biopharma downsizes to focus on autoimmune pipeline

cafead

Administrator
Staff member
  • cafead   Jul 26, 2024 at 11:32: AM
via Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programs and carry out a workforce reduction.

The company plans to fire 25% of its staff, which along with other cash reduction measures is expected to save Cue Biopharma $30m in operating expenses in 2025. The company added that following the restructuring its cash runway will extend to mid-2025.

article source